On August 19, Gilead Sciences rose 3.15% in regular trading, trading at $147.9/share, with turnover of $103 million. The rally marks a second consecutive session of gains following the company's announcement of a major oncology-focused acquisition.

On August 18, Gilead Sciences announced it would acquire cancer therapy developer Arcellx at an equity value of $7.8 billion, paying $115 per share in cash plus a $5 per share contingent value right, representing an 87% premium over Arcellx's prior closing price. The deal is widely viewed as a strategic move to significantly strengthen Gilead's oncology pipeline. Continued positive sentiment from the acquisition, combined with solid Q2 fundamentals — revenue of $7.8 billion beating estimates and full-year adjusted loss guidance narrowed to $0.30-$0.65 per share versus the analyst consensus of $0.75 loss — has sustained upward momentum in the stock.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)